LogicBio Therapeutics, Inc. (LOGC) financial statements (2021 and earlier)

Company profile

Business Address 65 HAYDEN AVE
LEXINGTON, MA 02421
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments705181
Cash and cash equivalents703381
Short-term investments 18 
Restricted cash and investments 0 
Receivables0  
Other undisclosed current assets221
Total current assets:735382
Noncurrent Assets
Operating lease, right-of-use asset61
Property, plant and equipment221
Restricted cash and investments110
Total noncurrent assets:831
TOTAL ASSETS:815683
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities443
Accounts payable011
Accrued liabilities332
Employee-related liabilities1  
Other liabilities0  
Other undisclosed current liabilities1  
Total current liabilities:643
Noncurrent Liabilities
Long-term debt and lease obligation1310 
Long-term debt, excluding current maturities810 
Operating lease, liability5 
Other undisclosed noncurrent liabilities(5)  
Total noncurrent liabilities:1310 
Total liabilities:19133
Stockholders' equity
Stockholders' equity attributable to parent614280
Common stock000
Additional paid in capital161110107
Accumulated other comprehensive income (loss) 0(0)
Accumulated deficit(100)(67)(27)
Total stockholders' equity:614280
TOTAL LIABILITIES AND EQUITY:815683

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Gross profit:3  
Operating expenses(35)(41)(18)
Operating loss:(32)(41)(18)
Nonoperating income (expense)(1)10
Other nonoperating expense(0)(0)(0)
Interest and debt expense(1)(1) 
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes11(0)
Loss from continuing operations before equity method investments, income taxes:(32)(40)(18)
Other undisclosed income from continuing operations before income taxes  0
Loss from continuing operations before income taxes:(32)(40)(18)
Income tax expense(0)(0)(0)
Net loss available to common stockholders, diluted:(33)(40)(18)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Net loss:(33)(40)(18)
Comprehensive loss:(33)(40)(18)
Other undisclosed comprehensive income, net of tax, attributable to parent 00
Comprehensive loss, net of tax, attributable to parent:(33)(40)(18)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: